ANAPTYSBIO, INC — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
AnaptysBio's Board approved Amendment No. 1 to its 2017 Equity Incentive Plan on August 11, 2026, effective upon stockholder approval. The amendment extends the plan's term by 10 years and establishes annual non-employee director compensation limits: $1,000,000 in value (cash + equity awards) in the director's first fiscal year of service, and $750,000 in subsequent fiscal years, commencing July 1, 2026. No specific dollar amounts of outstanding equity, share counts, or financial impact are disclosed.
Why this rating
Routine plan administration: extends equity vehicle and caps director pay—standard governance. No material business or revenue impact disclosed; no share buyback or issuance surprise.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.